AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

By P. Zarrinkar, R. Gunawardane, Merryl D. Cramer, M. Gardner, D. Brigham, B. Belli, Mazen W. Karaman, K. Pratz, Gabriel Pallares, Q. Chao and 6 more. Blood, 2009

635 citations recorded by the source corpus.

Subfields: Genetics, Hematology

View Paper: https://www.semanticscholar.org/paper/bb40daafdb4bea53f80ab91bd5dbb41bc6affef5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Mindy I. Davis
2. Jeremy P Hunt
3. S. Herrgård
4. P. Zarrinkar
5. P. Ciceri
6. L. Wodicka
7. Gabriel Pallares
8. D. K. Treiber

Citations in the corpus

• Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020, neutral): “AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).”
• Comprehensive analysis of kinase inhibitor selectivity (2011, background): “Data for 40 of the compounds against smaller assay panels have been published previousl”